|
rs28934576
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results show: (1) wild-type p53 stimulates the transcription of reporter genes with p53CON and RGC in their 5' region while most p53 mutants occurring in human cancers have lost this activity; (2) the R273H mutant retains transcriptional activity for the p53CON sequence but not RGC; (3) some mutants are temperature-sensitive for the transcriptional activity with the p53CON but not the RGC sequence; (4) p53 mutants vary in their ability to inhibit wild-type p53 transactivation but there is no difference between p53CON and RGC sequences; (5) lung cancer cells with endogenous mutant p53 proteins (M246I in H23 cells and R248L in H322 cells) retain transcriptional activity for the p53CON but not the RGC sequence.
|
8336941 |
1993 |
|
rs11540652
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Our results show: (1) wild-type p53 stimulates the transcription of reporter genes with p53CON and RGC in their 5' region while most p53 mutants occurring in human cancers have lost this activity; (2) the R273H mutant retains transcriptional activity for the p53CON sequence but not RGC; (3) some mutants are temperature-sensitive for the transcriptional activity with the p53CON but not the RGC sequence; (4) p53 mutants vary in their ability to inhibit wild-type p53 transactivation but there is no difference between p53CON and RGC sequences; (5) lung cancer cells with endogenous mutant p53 proteins (M246I in H23 cells and R248L in H322 cells) retain transcriptional activity for the p53CON but not the RGC sequence.
|
8336941 |
1993 |
|
rs1019340046
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results show: (1) wild-type p53 stimulates the transcription of reporter genes with p53CON and RGC in their 5' region while most p53 mutants occurring in human cancers have lost this activity; (2) the R273H mutant retains transcriptional activity for the p53CON sequence but not RGC; (3) some mutants are temperature-sensitive for the transcriptional activity with the p53CON but not the RGC sequence; (4) p53 mutants vary in their ability to inhibit wild-type p53 transactivation but there is no difference between p53CON and RGC sequences; (5) lung cancer cells with endogenous mutant p53 proteins (M246I in H23 cells and R248L in H322 cells) retain transcriptional activity for the p53CON but not the RGC sequence.
|
8336941 |
1993 |
|
rs750600586
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Direct sequencing of the mutant band revealed that one patient had a C to T transition at codon 138 (Ala to Val) and one patient had a G to C transversion at codon 139 (Lys to Asn). p53 mutations in germline cells in hereditary cancer syndromes predispose the family members to the development of malignancies.
|
8321049 |
1993 |
|
rs876660829
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Direct sequencing of the mutant band revealed that one patient had a C to T transition at codon 138 (Ala to Val) and one patient had a G to C transversion at codon 139 (Lys to Asn). p53 mutations in germline cells in hereditary cancer syndromes predispose the family members to the development of malignancies.
|
8321049 |
1993 |
|
rs587782529
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Thus, the R337C mutant retains some functional activity yet leads to a predisposition to cancer, suggesting that even partial inactivation of p53 oligomerization is sufficient for accelerated tumour progression.
|
9704931 |
1998 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The p53 codon 72 Arg/Pro polymorphism has been suggested to be associated with susceptibility to tobacco-related cancers, but this association remains controversial.
|
12065086 |
2002 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The p53 codon 72 Arg/Pro polymorphism has been suggested to be associated with susceptibility to tobacco-related cancers, but this association remains controversial.
|
12065086 |
2002 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The p53 codon 72 Arg/Pro polymorphism has been suggested to be associated with susceptibility to tobacco-related cancers, but this association remains controversial.
|
12065086 |
2002 |
|
rs876659384
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The E287X TP53 mutation segregated with the cancer phenotype in the family members from whom DNA samples were available.
|
15368100 |
2004 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Codon 72 exon 4 polymorphism (Arg72Pro) of the p53 gene has been implicated in cancer risk.
|
15633234 |
2005 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Statistically significant associations were noted between SNPs in beta-catenin and APOE and a positive family history of cancer (beta-catenin: p=0.034, APOE: p=0.033); tumor location and a DCC SNP (p=0.038) and the P53 R72P mutation and survival (p=0.0336).
|
15523694 |
2005 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Statistically significant associations were noted between SNPs in beta-catenin and APOE and a positive family history of cancer (beta-catenin: p=0.034, APOE: p=0.033); tumor location and a DCC SNP (p=0.038) and the P53 R72P mutation and survival (p=0.0336).
|
15523694 |
2005 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Codon 72 exon 4 polymorphism (Arg72Pro) of the p53 gene has been implicated in cancer risk.
|
15633234 |
2005 |
|
rs121912664
|
|
|
0.100 |
GeneticVariation |
BEFREE |
There was no association between the presence of germline or tissue R337H p53 mutation and malignancy at diagnosis.
|
15952083 |
2005 |
|
rs28934576
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Neither dicoumarol nor curcumin dissociated the complexes of NQO1 and the human cancer hot-spot p53 R273H mutant and therefore did not induce degradation of this mutant.
|
15809436 |
2005 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Codon 72 exon 4 polymorphism (Arg72Pro) of the p53 gene has been implicated in cancer risk.
|
15633234 |
2005 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Statistically significant associations were noted between SNPs in beta-catenin and APOE and a positive family history of cancer (beta-catenin: p=0.034, APOE: p=0.033); tumor location and a DCC SNP (p=0.038) and the P53 R72P mutation and survival (p=0.0336).
|
15523694 |
2005 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To explore the impact of the p53 PIN3-Arg72Pro haplotype on colorectal adenoma formation and progression to cancer.
|
17374954 |
2006 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer.
|
16721787 |
2006 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers.
|
16419081 |
2006 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer.
|
16721787 |
2006 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To explore the impact of the p53 PIN3-Arg72Pro haplotype on colorectal adenoma formation and progression to cancer.
|
17374954 |
2006 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers.
|
16419081 |
2006 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To explore the impact of the p53 PIN3-Arg72Pro haplotype on colorectal adenoma formation and progression to cancer.
|
17374954 |
2006 |